title: [Oral propranolol in the management of periorbital proliferating phase infantile hemangioma].
abstract: OBJECTIVE
  To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma.
  
  
  METHODS
  A retrospective review of patient medical records was performed. 12 patients (9 female, 3 male; 1.5-8.5 months, average 3.3 months) with periorbital proliferating phase infantile hemangioma underwent oral propranolol therapy. The dosage was slowly increased to 2 mg/kg daily in divided doses for a mean duration of 16 weeks (range 4 weeks-41 weeks). Therapeutic outcomes and safety were established by evaluating colour, size of lesion, duration of treatment and side-effects of treatment before and after treatment.
  
  
  RESULTS
  Of these, 9 had a signification reduction in colour and size of the lesions, 2 had no further growth. 1 is stopped therapy due to hypotension after drug administration. 11 other patients, although mild adverse effects were noted, no symptoms were severe enough to discontinue treatment.
  
  
  CONCLUSIONS
  Propranolol appears to be a safe and effective treatment in the management of periorbital proliferating phase infantile hemangioma.
authors.affiliation: Department of Plastic and Burn Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Zhong-fang
authors.initials: ZF
authors.lastname: Zhao
authors.forename: Ren-rong
authors.initials: RR
authors.lastname: Lü
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Ran
authors.initials: R
authors.lastname: Huo
authors.forename: Guang-qi
authors.initials: GQ
authors.lastname: Xu
authors.forename: Hong-bin
authors.initials: HB
authors.lastname: Fu
authors.forename: Xuan
authors.initials: X
authors.lastname: Guo
authors.forename: Jun-cheng
authors.initials: JC
authors.lastname: Wui
authors.forename: Ling-ling
authors.initials: LL
authors.lastname: Lin
mesh_terms: D002648:Child; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009918:Orbital Neoplasms / Q000188:drug therapy*; D011433:Propranolol / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D011433:Propranolol